Bioarray Genetics Presents at the 40th Annual San Antonio Breast Cancer Symposium

Bioarray Genetics announced today that the Company will be presenting a pivotal study at the upcoming 40th Annual San Antonio Breast Cancer Symposium on December 7th.

Bioarray conducted a 582-patient clinical validation study that confirms the company’s lead test’s ability to identify a subset of triple negative breast cancer patients with resistant disease and the poorest prognosis. The research results will be presented in a poster, titled “A Predictive Test for Neoadjuvant Chemotherapy in Breast Cancer.”

Read the full article here.

2018-04-26T20:57:56+00:00